The days are getting shorter as we "fall back” into standard time and it may be affecting your mood. While we settle into our ...

Mental health is a vital aspect of overall well-being, especially for students who face unique pressures and challenges. From ...

Efforts have been made in recent years to clarify the value of exercise as an adjunctive or independent treatment for major ...

Seasonal Affective Disorder (SAD) affects millions of Americans, and cases usually start to rise in late fall or early winter ...

The following is a summary of “Voice of depression: speech features as biomarkers for major depressive disorder,” published ...

Cybin (TSE:CYBN) has released an update. Cybin Inc. is set to unveil promising 12-month Phase 2 data for CYB003 in treating Major Depressive ...

The Horizon 3.0 TMS Therapy System is a computerized, noninvasive medical device that directs electrical currents at different regions of the cerebral cortex.

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication ...